Leprosy Treatment Market, By Drug Class (Antibacterial, Leprostatics, Antitubercular, Others), By Route Of Administration (Oral, Injectable, Topical), And Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, And Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) - Trends, Analysis, and Forecast till 2030

Leprosy also called as a Hansen’s Disease is a serious medical condition in which person suffered from chronic infection. Leprosy caused by a Mycobacterium leprae bacteria. Leprosy is principally a granulomatous disease & it affects the skin, upper respiratory tract mucosal surfaces, peripheral nerves and the eyes majorly. The symptoms of leprosy include reddish skin lesions, loss of sensation, and weakness of hands and muscles. It is likely to cause nerve damage so as to induce muscle numbness. It is a communicable disease that can propagated through contact with cough or phlegm of the affected person. Generally, it is prevalent in low-income countries & malnutrition as well as weak immune system are other significant risk factors of leprosy. Leprosy can be cured by the Multidrug Therapy (MDT) which includes mixture of drugs like rifampicin, clofazimine and dapsone.  The global leprosy treatment market accounted for US$ 2.65 billion in 2020 and is estimated to be US$ 4.09 billion by 2030 and is anticipated to register a CAGR of 4.50%.

Impact of Covid-19 pandemic on market

In all nations, the COVID-19 pandemic had a substantial impact on health services. WHO report revealed that COVID-19 pandemic has impact on leprosy treatment like reassignment of staff, cessation of community-based activities and active case-finding, delays in receiving MDT supplies at the national level and occasional stock-outs at the subnational and health facility levels, and limited monitoring of nerve function impairment and treatment of reaction. Although this pandemic affected progress of this market in general, but it provided opportunities to enhance digital health initiatives for diagnosis as well as for monitoring & training to strengthen the skills of staffs.

In all nations, the COVID-19 pandemic had a substantial impact on health services. WHO report revealed that COVID-19 pandemic has impact on leprosy treatment like reassignment of staff, cessation of community-based activities and active case-finding, delays in receiving MDT supplies at the national level and occasional stock-outs at the subnational and health facility levels, and limited monitoring of nerve function impairment and treatment of reaction. Although this pandemic affected progress of this market in general, but it provided opportunities to enhance digital health initiatives for diagnosis as well as for monitoring & training to strengthen the skills of staffs.

Novel Therapies, Government Initiatives & “Towards Zero Leprosy”

Increasing rate of the prevalence of skin diseases increase the demand of Leprosy treatments. Also, government initiatives & favorable reimbursement are propelling factors for growth of the leprosy treatment market. Furthermore, findings of novel therapies also has positive impact on this market. Key companies in the market are focused on various business strategies such as partnership and collaboration & gaining product approvals, in order to provide better solution for leprosy treatment. Additionally, With the help of the Global Leprosy Strategy 2021–2030 “Towards zero leprosy” which was developed through a broad consultative process with all major stakeholders will effect positively on this market in upcoming years.

High cost & Lack of awareness

The high cost of drugs and lack of awareness as well as fear among people is expected to hamper the growth of the market for Leprosy Treatment. However, developing economies with low health care expenditure and least availability of medical facilities for proper diagnosis of diseases are projected to restrain the leprosy treatment market in developing countries during the forecast period.

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

On the basis of Drug Class, the global leprosy treatment market is segmented into Antibacterial, Leprostatics, Antitubercular & Others drugs. Based on Route of Administration leprosy treatment market is divided into Oral, Injectable & Topical. On the basis of Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, Drug stores and Online Pharmacies.

Regional Insights:

Source: Prophecy Market Insights

On region the global leprosy treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has the greatest market for leprosy treatment market, followed by Europe due to favorable reimbursement scenario, high expenditure on health care, rapid adoption of new technologies, rising awareness & high disposable income in the region. Also, Asia-Pacific region is predicted to have a strong growth rate in the leprosy treatment market in the next years because of rising prevalence of leprosy, increasing government initiatives, and rapidly developing health care infrastructure in the region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global leprosy treatment market report based on Drug Class, Route of Administration, Distribution Channel and Region.                                                               

Global Oncology Drug Market, By Region:

• North America
  • • • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the leprosy treatment market includes the prominent player operating in the leprosy treatment market includes GlaxoSmithKline plc, Macleods Pharmaceuticals, Cadila Pharmaceuticals, Novartis AG, Systopic Laboratories Pvt. Ltd., AstraZeneca plc, Zydus Cadila, Merck & Co., Inc., Sanofi & HDT Biotech Corporation.

• GlaxoSmithKline plc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Novartis International AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

•   Macleods Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Cadila Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Systopic Laboratories Pvt. Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AstraZeneca plc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck & Co., Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Zydus Cadila
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sanofi
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• HDT Biotech Corporation.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

 “*” marked represents similar segmentation in other categories in the respective section